Drug Profile
LY 3006072
Alternative Names: LY3006072Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Undefined(In volunteers) in USA (PO, Capsule)
- 01 Nov 2012 Eli Lilly completes a phase I trial in Healthy volunteers in USA (NCT01640249)
- 26 Jul 2012 Phase-I clinical trials in Undefined indication in USA (PO)